nafamostat
mesyl
nm
synthet
serin
proteas
inhibitor
first
place
market
japan
tobacco
approv
treat
inflammatoryrel
diseas
pancreat
recent
increas
number
studi
highlight
promis
effect
nm
inhibit
cancer
progress
alon
combin
treatment
studi
shown
nm
attenu
variou
malign
tumor
includ
pancreat
colorect
gastric
gallbladd
hepatocellular
cancer
review
base
sever
activ
pathway
includ
canon
nuclear
signal
pathway
tumor
necrosi
factor
signal
pathway
tumorigenesisrel
tryptas
secret
mast
cell
summar
anticanc
properti
nm
exist
studi
vitro
vivo
addit
efficaci
side
effect
nm
cancer
patient
summar
detail
clarifi
nm
antitumor
activ
clinic
trial
devot
valid
clinic
applic
underli
mechan
need
futur
cancer
worldwid
public
health
problem
major
caus
death
recent
year
current
effect
modal
cure
cancer
includ
radiat
surgeri
drug
among
therapeut
approach
chemotherapi
indispens
tumor
therapi
prolong
live
mani
patient
past
decad
howev
treatment
failur
side
effect
common
chemotherapi
advers
influenc
patient
surviv
qualiti
life
thu
huge
demand
power
chemotherapeut
agent
reduc
side
effect
provid
increas
surviv
benefit
cancer
patient
recent
increas
studi
indic
proteas
inhibitor
suppress
tumor
growth
progress
particular
sever
proteas
inhibitor
bortezomib
carfilzomib
ixazomib
approv
unit
state
food
drug
administr
fda
clinic
use
treatment
multipl
myeloma
find
suggest
proteas
inhibitor
broad
prospect
develop
anticanc
agent
nafamostat
mesyl
nm
also
known
dihydrochlorid
broadspectrum
serin
proteas
inhibitor
synthes
fujii
et
al
five
year
later
compani
call
japan
tobacco
brought
market
nm
usual
use
treat
pancreat
dissemin
intravascular
coagul
dic
system
inflammatori
respons
syndrom
via
suppress
thrombin
plasmin
kallikrein
trypsin
cl
esteras
complement
system
well
factor
viia
xa
xiia
coagul
cascad
grow
conting
research
focus
potenti
anticanc
effect
nm
earli
one
studi
confirm
nm
inhibit
liver
metastasi
concentr
colon
adenocarcinoma
first
uncov
put
effect
cancer
therapi
subsequ
nm
proven
downregul
express
matrix
vascular
endotheli
growth
factor
vegf
transform
growth
factor
beta
secret
tumor
cell
head
neck
squamou
cell
carcinoma
nm
inhibit
angiogenesi
tumor
invas
furthermor
mander
et
al
report
nm
significantli
inhibit
prolifer
migrat
invas
tripleneg
breast
cancer
identifi
vitro
vivo
moreov
nm
revers
immun
resist
induc
interferongamma
ifng
method
increas
program
cell
death
express
lung
pancreat
cancer
current
explor
antitumor
effect
nm
full
swing
report
concentr
exist
evid
regard
antitumor
activ
nm
discuss
potenti
mechan
nm
target
cancer
addit
evalu
possibl
nm
use
futur
clinic
applic
effect
advers
effect
nm
also
discuss
far
multipl
studi
uncov
potent
anticanc
abil
nm
evid
nm
inhibit
cancer
cell
prolifer
adhes
invas
suppress
tumor
growth
anim
model
furthermor
nm
initi
apoptosi
vitro
vivo
addit
nm
capac
provid
improv
sensit
tumor
convent
clinic
treatment
furthermor
synthet
serin
proteas
inhibitor
interest
grow
use
nm
tumor
progress
induc
mcderiv
tryptas
tumor
cell
prolifer
angiogenesi
stimul
tryptas
revers
nm
herein
investig
nm
exert
anticanc
effect
discuss
mechan
nm
target
figur
nuclear
induc
transcript
factor
compris
famili
member
design
relb
crel
bind
consensu
dna
sequenc
promot
region
heterodim
homodim
activ
target
gene
far
two
major
signal
pathway
consid
mediat
activ
canon
noncanon
signal
pathway
canon
pathway
activ
occur
via
degrad
inhibitor
famili
consist
characterist
member
sever
structur
relat
protein
cytoplasm
bind
rest
state
stimul
stress
infect
factor
kinas
ikk
complex
compos
catalyt
regulatori
subunit
activ
subsequ
lead
phosphoryl
phosphoryl
undergo
ubiquityl
proteasomemedi
degrad
promot
releas
transloc
dimer
regul
gene
transcript
entir
canon
pathway
induc
activ
heterodim
includ
crel
display
rapid
transient
characterist
contrast
activ
noncanon
pathway
gener
relb
slow
persist
speed
involv
base
two
pathway
activ
mediat
wide
varieti
human
diseas
particularli
cancer
frequent
hyperactiv
sever
cancer
subunit
crucial
role
tumor
prolifer
migrat
resist
radiotherapi
chemotherapi
although
canon
signal
pathway
extens
studi
kind
cancer
still
new
breakthrough
occur
field
instanc
breast
lung
cancer
inflammatori
cytokin
tumor
necrosi
factor
tnf
activ
signal
transduc
activ
transcript
brain
metastat
cell
respons
stimul
carcinomaastrocyt
gap
junction
compos
protocadherin
connexin
lead
tumor
growth
chemoresist
relationship
upstream
downstream
inflammatori
cytokin
intens
studi
research
reveal
novel
role
carcinomaastrocyt
interact
model
grinbergbley
et
al
report
defici
crel
subunit
could
suppress
gener
mainten
activ
regulatori
cell
imped
immun
toler
mice
lack
crel
experienc
delay
melanoma
growth
enhanc
antiprogram
cell
immunotherapi
respons
sinc
contain
complex
primarili
respons
cellular
activ
respons
target
crel
may
prevent
undesir
side
effect
addit
investig
focus
interplay
malign
noncanon
pathway
recent
year
human
glioblastoma
cell
transcript
mutant
telomeras
tert
promot
reactiv
cooper
etwentysix
famili
transcript
factor
promot
regul
tert
transcript
tumorigen
accordingli
target
critic
subunit
dysfunct
upstream
pathway
lead
activ
may
afford
cancer
patient
consider
treatment
prospect
recent
nm
shown
potent
inhibit
canon
pathway
suppress
aggress
behavior
variou
cancer
pancreat
cancer
colorect
gastric
hepatocellular
carcinoma
studi
uwagawa
et
al
nm
found
inhibit
phosphoryl
dnabind
activ
dosedepend
timedepend
manner
pancreat
cancer
cell
anoth
studi
show
activ
intercellular
adhes
vegf
downstream
transcript
target
gene
stifl
owe
nminduc
suppress
activ
inhibit
pancreat
cancer
cell
adhes
anoiki
invas
moreov
nm
could
significantli
decreas
activ
reduc
tumor
growth
neovascular
prolong
surviv
apoptosi
modul
pancreat
vivo
model
research
past
decad
demonstr
nm
inhibit
prolifer
induc
apoptosi
nuclear
transloc
caspas
famili
regul
colorect
gastric
hepatocellular
carcinoma
cell
vivo
model
colorect
hepatocellular
gastric
cancer
nm
confirm
effect
antineoplast
properti
reduc
diamet
volum
weight
tumor
singl
agent
furthermor
aberr
activ
signal
proven
one
potenti
mechan
underli
chemotherapi
radiotherapi
failur
intriguingli
function
nm
enhanc
sensit
chemotherapi
radiotherapi
though
inhibit
activ
report
pancreat
gastric
gallbladd
hepatocellular
cancer
tabl
previou
research
report
combin
nm
chemotherapeut
agent
oxaliplatin
gemcitabin
paclitaxel
nabpaclitaxel
could
increas
sensit
singleag
combin
chemotherapi
pancreat
cancer
chemosensit
abil
nm
mainli
report
downregul
phosphoryl
gener
synergist
cytotox
inhibit
activ
previou
research
report
combin
nm
chemotherapeut
agent
oxaliplatin
gemcitabin
paclitaxel
nabpaclitaxel
could
increas
sensit
singleag
combin
chemotherapi
pancreat
cancer
chemosensit
abil
nm
mainli
report
downregul
phosphoryl
gener
synergist
cytotox
inhibit
activ
vivo
studi
also
demonstr
nm
sensit
cell
chemotherapi
inhibit
pancreat
tumor
growth
similar
studi
reveal
nm
inhibit
activ
hepatocellular
carcinoma
gallbladd
gastric
cancer
vitro
vivo
specif
treatment
nm
combin
gemcitabin
gallbladd
cancer
paclitaxel
gastric
cancer
hepatocellular
carcinoma
depress
activ
stimul
anoth
studi
also
confirm
combin
nm
sensit
oxaliplatininduc
activ
via
suppress
phosphoryl
colorect
cancer
result
reduc
cell
prolifer
increas
apoptosi
vitro
decreas
tumor
growth
vivo
nm
also
shown
act
radiosensit
via
inhibit
colorect
pancreat
cancer
note
except
dysfunct
dysregul
result
increas
express
respons
nm
treatment
combin
gy
ioniz
radiat
ir
pancreat
cancer
number
studi
indic
activ
respons
dna
damag
ioniz
radiat
modul
activ
besid
classic
strategi
novel
molecular
inhibit
confirm
improv
antitumor
effect
nm
pathway
relat
signal
haruki
et
al
found
addit
glycogen
synthas
inhibitor
nm
significantli
decreas
activ
inhibit
cell
prolifer
pancreat
cancer
though
use
inhibitor
alon
allevi
activ
also
demonstr
one
isom
dephosphoryl
protein
phosphatas
phosphoryl
act
inact
form
treat
nm
case
confirm
nm
combin
inhibitor
significantli
upregul
phosphoryl
promot
cellular
apoptosi
compar
nm
alon
suggest
nm
may
improv
therapeut
outcom
pancreat
cancer
taken
togeth
nm
alon
combin
anticanc
treatment
play
power
role
candid
intervent
signal
cancer
therapi
apoptosi
cellular
suicid
program
play
pivot
role
repress
cancer
develop
among
variou
mechan
contribut
apoptosi
tumor
necrosi
factor
signal
pathway
emerg
one
key
mediat
ubiquit
express
almost
cell
human
bodi
primari
mediat
stimul
solubl
tnf
tnf
bind
activ
proapoptosi
pathway
antiapoptosi
pathway
affect
canon
signal
base
subsequ
format
complex
one
hand
proapoptot
cascad
reaction
consist
multipl
protein
fasassoci
death
domain
fadd
tnf
receptorassoci
death
domain
tradd
receptorinteract
protein
kinas
occur
form
protein
design
complex
ii
gener
polyadenosin
ribos
polymeras
parp
induc
apoptosi
nevertheless
cascad
curb
sever
factor
cellular
inhibitor
apoptosi
gene
suppress
apoptosi
promot
cell
surviv
hand
complex
also
recruit
seri
protein
includ
tnf
receptor
associ
factor
tradd
among
recruit
modifi
polyubiquitin
chain
complex
known
complex
lead
activ
canon
signal
pathway
therefor
target
proapoptot
pathway
counteract
role
canon
signal
pathway
stimul
antiapoptot
transcript
program
may
repres
pivot
approach
cancer
therapi
nminduc
apoptosi
identifi
cultur
cell
anim
model
demonstr
human
cancer
pancreat
colorect
gastric
hepatocellular
gallbladd
cancer
multipl
sourc
data
support
nm
acceler
apoptosi
dual
way
prevent
activ
antiapoptot
process
also
act
initi
signal
molecul
apoptosi
uwagawa
et
al
demonstr
nm
upregul
express
dosedepend
manner
elev
phosphoryl
fadd
timedepend
manner
base
activ
two
mediat
inhibit
activ
express
upregul
facilit
apoptosi
furthermor
numer
studi
report
nm
plu
chemotherapeut
agent
ir
trigger
express
cleav
parp
compar
use
chemotherapi
ir
alon
pancreat
colorect
gastric
gallbladd
hepatocellular
cancer
close
follow
downregul
variou
form
specif
nm
inhibit
oxaliplatininduc
gemcitabineinduc
activ
pancreat
cancer
find
suggest
nm
potenti
antitumor
effect
via
inhibit
express
posit
feedback
loop
restrain
activ
neg
regul
express
turn
repress
activ
promot
apoptosi
thu
import
consider
anticanc
field
induct
downstream
apoptot
pathway
nm
tryptas
trypsinlik
serineproteinas
molecular
weight
kda
abund
secret
mast
cell
mc
tryptas
contain
hydrolyz
peptid
bind
carboxyl
terminu
basic
residu
tetramer
structur
consist
noncoval
link
subunit
adequ
activ
form
store
mc
two
type
tryptas
express
human
mc
alpha
beta
major
circul
isoform
major
form
store
secretori
granul
normal
tryptas
act
indic
provid
inform
distribut
activ
statu
mc
level
serum
tryptas
may
reflect
diseas
state
allergi
reaction
mastocytosi
inflammatori
reaction
nevertheless
increas
evid
support
view
tryptas
vital
mediat
biolog
pathway
includ
tissu
remodel
carcinogenesi
current
enorm
number
studi
uncov
associ
mcreleas
tryptas
tumor
progress
especi
neovascular
instanc
posit
linear
correl
demonstr
serum
mast
cell
densiti
posit
tryptas
mcdpt
microvascular
densiti
endotheli
area
patient
undergo
surgeri
colorect
breast
gastric
cancer
indic
serum
tryptas
level
may
repres
novel
surrog
angiogen
marker
cancer
patient
involv
tryptas
degrad
extracellular
matrix
releas
angiogen
factor
vegf
receptor
fibroblast
growth
clearli
demonstr
base
find
tryptas
process
tryptas
act
might
becom
potenti
drug
target
cancer
therapi
pharmacolog
properti
nm
make
compound
interest
candid
new
anticanc
agent
inhibit
tryptas
colon
pancreat
cancer
yoshii
et
al
identifi
colon
carcinoma
nm
block
cell
prolifer
induc
treatment
tryptas
proteaseactiv
concentrationdepend
fashion
stimul
tryptas
mediat
prolif
effect
via
phosphoryl
mitogenactiv
protein
kinas
colon
carcinoma
addit
upregul
mmp
express
plasminogen
activ
lead
degrad
extracellular
matrix
becom
hallmark
poor
prognosi
combin
mcdpt
unclear
whether
nm
directli
inhibit
express
exert
antiprolif
effect
similar
inhibitori
effect
nm
tryptaseinduc
cell
prolifer
observ
pancreat
cancer
guo
et
al
also
demonstr
nm
possess
abil
revers
tube
format
caus
tryptas
via
inhibit
express
angiogenesisrel
gene
wellknown
target
receptor
agonist
regul
vascular
matur
stabil
date
investig
nm
inhibitori
effect
tryptas
anticanc
therapi
rel
scarc
limit
vitro
studi
although
applic
nm
mention
possibl
research
direct
studi
mechan
target
tryptas
cancer
therapi
infanc
studi
need
vitro
vivo
futur
nm
synthet
lowmolecularweight
serin
proteas
inhibitor
clinic
use
acut
pancreat
appli
anticoagul
extracorpor
circul
support
treatment
short
halflif
time
min
evid
illustr
clinic
use
pancreat
suggest
anim
model
illustr
nm
decreas
mortal
rat
experiment
acut
pancreat
model
dosedepend
manner
infus
dose
mgkgmin
aspect
anticoagul
retrospect
studi
indic
nm
could
substitut
heparin
applic
extracorpor
membran
oxygen
ecmo
novel
rescu
measur
circulatori
andor
respiratori
failur
result
show
nm
reduc
anticoagul
valu
patient
safe
level
infus
rate
mgkg
per
hour
patient
acut
kidney
injuri
receiv
continu
renal
replac
crrt
therapi
singlecent
random
studi
perform
found
mean
filter
lifespan
represent
treatment
efficaci
significantli
longer
patient
receiv
nm
without
nm
advers
event
associ
nm
administr
note
hematolog
malign
patient
diagnos
dic
dic
resolut
rate
day
treatment
nm
mgkgday
compar
proteas
inhibitor
gabex
mesyl
gm
signific
differ
dic
resolut
rate
two
inhibitor
respect
cancer
therapi
three
studi
conduct
explor
possibl
nm
clinic
applic
pancreat
tumor
treat
combin
nm
gemcitabin
chemotherapi
phase
studi
perform
patient
enrol
regimen
contain
administr
gemcitabin
fix
dose
mgm
min
day
cycl
accompani
administr
nm
start
via
portcathet
system
h
infus
gemcitabin
start
dose
nm
mgkg
increment
mgkg
mgkg
patient
experienc
doselimit
toxic
effect
level
increment
dose
case
recommend
dose
nm
combin
fulldos
gemcitabin
mgkg
next
base
recommend
dosag
phase
trial
singlearm
phase
ii
studi
occur
singl
center
evalu
treatment
efficaci
patient
unresect
metastat
pancreat
cancer
overal
respons
rate
patient
requir
opioid
cancerrel
pain
decreas
intak
evid
regimen
reveal
effect
improv
compar
standard
chemotherapi
gemcitabin
final
retrospect
singlecent
studi
jaundic
ascit
high
lymphocyt
count
high
serum
level
investig
poor
prognost
factor
overal
surviv
patient
unresect
pancreat
cancer
anticoagul
risk
bleed
one
common
advers
effect
associ
nm
use
retrospect
studi
found
nm
mg
mix
dextros
ml
water
infus
rate
mgh
significantli
increas
bleed
complic
patient
receiv
ecmo
compar
patient
receiv
heparin
therapi
howev
patient
receiv
crrt
use
nm
tend
correl
decreas
incid
bleed
complic
compar
use
unfraction
heparin
vs
furthermor
headach
nausea
fever
observ
prospect
observ
studi
includ
patient
leukocytapheresi
kim
et
al
report
case
rare
advers
reaction
anaphylact
shock
caus
nm
korea
infus
nm
hemodialysi
hematolog
malign
patient
dic
retrospect
studi
found
advers
event
hyperkalemia
hyponatremia
commonli
observ
patient
receiv
nm
mgkgday
compar
gm
find
indic
hint
explor
advers
effect
cancer
therapi
unresect
pancreat
cancer
vivo
studi
found
known
advers
effect
nm
hyperkalemia
hyponatremia
hepatopathi
compar
mice
treat
nm
dosag
pb
three
time
week
week
moreov
anoth
vivo
studi
pancreat
cancer
show
signific
differ
liver
toxic
combin
inject
nm
compar
inject
compound
alon
singlearm
singl
center
phase
ii
trial
leukopenia
neutropenia
primarili
appear
pancreat
cancer
patient
receiv
nm
mgkg
continu
region
arteri
infus
gemcitabin
mgm
intraven
day
thu
superior
nm
reduc
advers
reaction
obviou
current
clinic
therapi
random
control
studi
still
necessari
detect
advers
reaction
rate
occurr
light
detail
find
nm
exhibit
low
toxic
advantag
base
combin
therapi
tradit
chemotherapeut
agent
suggest
combin
treatment
nm
chemotherapi
may
repres
novel
promis
strategi
cancer
potenti
immun
therapi
nm
date
sever
contract
point
regard
immunomodulatori
function
nm
reduc
granzym
activ
cytotox
lymphocyt
cytolysi
nm
suppress
local
product
attenu
cell
autoreact
experiment
autoimmun
encephalomyel
stroke
rat
model
nm
decreas
gener
proinflammatori
factor
induc
nitric
oxid
synthas
elicit
express
antiinflammatori
mediat
contrari
identifi
nm
play
role
immun
activ
enhanc
nm
effect
increas
activ
lymphocyt
natur
killer
cell
hepat
resect
patient
also
nm
induc
tcell
prolifer
play
role
coadjuv
peptid
vaccin
mention
major
anticanc
mechan
nm
downregul
activ
fujiwara
et
al
demonstr
nm
could
act
immunotherapi
sensit
combin
gemcitabin
hepatocellular
carcinoma
pancreat
cancer
also
nm
demonstr
affect
antiangiogen
activ
mcsderiv
tryptas
colon
carcinoma
exist
evid
suggest
nm
inclin
show
immun
activ
activ
antitumor
therapi
although
role
nm
inflammatoryrel
pathway
report
direct
evid
nm
antitumor
effect
immun
cell
still
clarifi
crucial
factor
inhibit
cellmedi
respons
previou
studi
uncov
nm
revers
upregul
lung
cancer
pancreat
cancer
cell
figur
pivot
immun
escap
factor
human
leukocyt
antigenabc
hlaabc
may
help
differenti
benign
malign
indetermin
pulmonari
lesion
studi
homma
et
al
confirm
nm
influenc
hlaabc
upregul
lung
cancer
pancreat
cancer
suggest
nm
may
improv
treatment
immun
resist
cancer
inhibit
effect
nm
associ
immun
evas
pathway
includ
protein
kinas
b
akt
interferon
regulatori
extracellular
signalregul
kinas
signal
pathway
interest
inhibit
upregul
found
research
henc
underli
mechan
nm
exert
inhibit
remain
explor
studi
warrant
figur
correl
nm
inflammatori
factor
investig
inhibit
effect
nm
human
tumor
evalu
avail
nm
cancer
therapi
herein
briefli
compar
function
clinic
valu
nm
proteas
inhibitor
seri
synthet
serin
proteas
inhibitor
gm
bortezomib
use
clinic
applic
gm
therapeut
use
dic
acut
pancreat
asian
countri
antitumor
effect
nm
analyz
compar
gm
postendoscop
retrograd
cholangiopancreatographi
pancreat
pep
wound
heal
dic
similar
nm
gm
exert
signific
antitumorigen
effect
suppress
express
promot
activ
human
pancreat
cancer
cell
addit
vitro
vivo
studi
report
gm
attenu
mmp
activ
reduc
cell
growth
invas
angiogenesi
colon
cancer
effect
also
identifi
seri
colorect
cancer
cell
kra
braf
mutat
sinc
genet
mutat
emerg
predict
biomark
patient
might
fail
egfrtarget
therapi
preliminari
find
indic
gm
may
repres
promis
therapeut
agent
metastat
colorect
cancer
howev
pharmacolog
mechan
clinic
studi
gm
cancer
therapi
still
limit
furthermor
vitro
experi
demonstr
nm
could
effect
suppress
pancreat
proteas
activ
gm
time
metaanalysi
demonstr
decreas
risk
pep
correl
nm
associ
gm
wound
heal
abil
nm
also
identifi
effici
gm
rat
model
howev
associ
gm
nm
observ
hematolog
malignanciesinduc
dic
signific
differ
dic
resolut
rate
gm
nm
group
frequenc
advers
effect
rel
higher
nm
group
base
discoveri
compar
effect
nm
gm
suggest
potenti
usag
nm
cancer
treatment
studi
still
need
valid
safeti
efficaci
nm
clinic
trial
proteas
inhibitor
bortezomib
first
drug
approv
fda
multipl
myeloma
treatment
compar
bortezomib
nm
show
analog
inhibitori
effect
activ
express
moreov
preclin
clinic
data
identifi
nm
could
sensit
solid
tumor
chemotherapi
classic
chemoradiotherapi
nevertheless
fdaapprov
proteas
inhibitor
bortezomib
observ
mainli
distribut
blood
andor
bone
marrow
instead
solid
tumor
consid
limit
current
proteas
inhibitor
nm
may
appli
treatment
solid
tumor
new
aspect
summari
evid
indic
prospect
nm
boarder
clinic
applic
desir
even
current
use
asian
countri
far
nm
approv
treat
diseas
digest
hematolog
system
pancreat
dic
studi
confirm
potenti
clinic
use
nm
variou
diseas
herein
summar
potenti
pharmacolog
action
nm
nontumor
diseas
distribut
nervou
circulatori
respiratori
system
infecti
vivo
model
nervou
system
exampl
cerebr
ischemia
transient
middl
cerebr
arteri
occlus
rat
indic
bloodbrain
barrier
bbb
protect
function
nm
inhibit
thrombin
symptom
neuron
damag
brain
infarct
brain
oedema
motor
dysfunct
caus
impair
bbb
could
reduc
nm
treatment
moreov
nm
regul
cardiovascular
function
increas
nitric
oxid
gener
via
akteno
signal
pathway
indic
nm
might
serv
safeguard
prevent
cardiovascular
diseas
asthma
one
seriou
respiratori
diseas
world
rat
model
asthma
treatment
nm
show
decreas
eosinophil
neutrophil
infiltr
decreas
level
inflammatori
factor
bronchoalveolar
lavag
fluid
also
nuclear
activ
reduc
lung
tissu
indic
applic
function
nm
respiratori
system
antimicrobi
activ
nm
inman
et
al
found
nm
exert
dosedepend
inhibit
chlamydi
infect
vitro
vivo
model
show
nm
could
effect
minim
patholog
featur
chlamydialinduc
arthriti
includ
inflammatori
infiltr
joint
damag
addit
nm
could
inhibit
middl
east
respiratori
syndrom
coronaviru
infect
ebola
viru
diseas
vitro
studi
obvious
conclud
divers
antiinflammatori
modul
abil
nm
may
provid
hope
clinic
applic
futur
pharmaceut
develop
current
detail
mechan
nm
foster
inhibit
phosphoryl
malign
cancer
cell
remain
elus
molecul
regul
nm
tryptasemedi
angiogenesi
also
remain
unknown
point
modulatori
effect
nm
tumor
growth
distinct
particularli
combin
chemoand
radiotherapi
addit
clinic
studi
essenti
identifi
patholog
signific
nm
cancer
onset
compar
therapeut
respons
convent
therapi
alon
combin
nm
furthermor
immun
involv
nm
worthi
deepli
dig
either
immunoadjuv
therapi
directli
immunocyt
sensit
nm
serin
proteas
inhibitor
associ
inhibit
tumor
progress
variou
tumor
herein
summar
pharmacolog
mechan
evalu
clinic
applic
nm
cancer
therapi
current
research
demonstr
nm
block
canon
signal
target
cleavag
caspas
famili
tryptas
mast
cell
improv
therapeut
outcom
potenti
novel
anticanc
agent
nm
valid
amelior
cancer
therapi
resist
avoid
immun
resist
exist
clinic
data
show
rel
prefer
efficaci
safeti
nm
treatment
compar
proteas
inhibitor
nm
compar
antitumor
activ
advantag
human
pancreat
colorect
cancer
evid
highlight
superior
nm
nevertheless
question
remain
whether
nm
could
use
treatment
cancer
patient
addit
preclin
clinic
studi
essenti
conduct
yy
xc
zx
wrote
review
articl
xc
zx
sz
xw
wl
lq
jw
xy
qs
zg
perform
administr
technic
support
yy
design
studi
contribut
manuscript
prepar
author
review
approv
final
version
manuscript
